U
PTLA

UBS’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

UBS’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$80K Buy
3,175
+771
+32% +$20.3K ﹤0.01% 6261
2014
Q2 		$70K Sell
2,404
-426
-15% -$10.3K ﹤0.01% 6413
2014
Q1 		$73K Buy
2,830
+1,530
+118% +$40.8K ﹤0.01% 6374
2013
Q4 		$33K Buy
+1,300
New +$31.6K ﹤0.01% 7529

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

UBS's PTLA Position: Q3 2014 in Review

UBS increased its Portola Pharmaceuticals, Inc. (PTLA) stake by 32% in Q3 2014, buying an estimated $20.3K and bringing the position to 3,175 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #6261.

UBS first reported a position in PTLA in Q4 2013 and has held it in 4 quarters since. 108 funds tracked by Wall St. Rank hold PTLA as of Q3 2014.

  • UBS held 3,175 shares of Portola Pharmaceuticals, Inc. worth $80K as of Q3 2014.
  • UBS bought 771 Portola Pharmaceuticals, Inc. shares in Q3 2014, an estimated $20.3K.
  • Portola Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6261 holding.
  • UBS first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and has held it in 4 quarters since.
  • 108 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.